Compass Therapeutics appoints Barry Shin as CFO; Neil Lerner as PAO

Compass Therapeutics, Inc.

Barry Shin named CFO effective Dec 9, 2024; base salary $475K, target bonus 45%, sign-on $50K, and equity grants of 800K shares total.
Neil Lerner appointed principal accounting officer; he was VP of Finance since November 2020.
Shin replaces Thomas Schuetz as principal financial officer; Schuetz remains CEO.
Press release highlights 2025 catalysts: topline data for CTX-009 expected in Q1 2025.
Shin previously served as CFO/COO at Trevena and held investment banking roles at Mizuho, Guggenheim, and Piper Sandler.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.